Blog Details

Forthcoming Launches of NASH Therapeutics to Drive Growth of NASH Drugs Market

Date: 5th Jul 2020 | Category: Pharma & Healthcare

The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach US$84.34 billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029. The factors such as rising healthcare expenditure, increasing pharmaceutical R&D expenditure, surging diabetic population, escalating obese population, unmet medical needs and sedentary lifestyles are expected to drive the growth of the market. However, the market growth would be challenged by lethargic drug approval process, high treatment cost and less definitive diagnostic methods for NASH/NAFLD. A few notable trends include surging market penetration for NASH major drugs, increasing prevalence of NASH, progressing NASH diagnosis methods and biomarkers, NASH pipeline drugs under development and growth in e-commerce pharmaceutical products sales. 

The global non-alcoholic steatohepatitis (NASH) drugs market has two major segments, based on drug classes - Off-Label drugs and Therapeutic Drugs. The current NASH drugs market is wholly occupied by off-label drugs as there are no clinically approved medicines for the treatment of NASH. However, certain therapeutic drugs, from large pharmaceutical drugs, are expected to enter the market in coming years, with considerable market share. The need for definitive NASH treatment would lead to strong market penetration of the therapeutic drugs during the forecasted period.

The fastest growing regional market would be the U.S., due to the increasing prevalence of NASH, along with forthcoming launches of various NASH therapeutic drugs. Moreover, Europe is also expected to hold a significant share in the global NASH therapeutics market, owing to the growing awareness amongst the inhabitants, regarding NASH diagnosis and treatment methods. 

Scope of the report:

The report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market, segmented into Off Label Drugs and Therapeutic Drugs sub markets.

The major regional markets (the U.S., Europe and Rest of World) have been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth. 

The competitive landscape of the market, along with the company profiles of leading players (Bristol Myers Squibb, Gilead Sciences, Allergan Plc. (Tobira), Intercept Pharmaceuticals, Galmed Pharmaceuticals and Genfit SA) are also presented in detail.

Key Target Audience:

NAFLD/NASH Drugs Manufacturers

Chemical Suppliers

End Users (Hospital, Medical centers, Clinical Institutes)

Healthcare Consulting Firms 

Investment Banks

Government Bodies & Regulating Authorities